Zobrazit minimální záznam

Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study

dc.contributor.authorGojda, Jan
dc.contributor.authorKoudelková, Kateřina
dc.contributor.authorOuřadová, Anna
dc.contributor.authorLang, Alexander
dc.contributor.authorKrbcová, Magdaléna
dc.contributor.authorGvozdeva, Alexandra
dc.contributor.authorŠebo, Viktor
dc.contributor.authorSlagmolen, Lotte
dc.contributor.authorPotočková, Jana
dc.contributor.authorTůma, Petr
dc.contributor.authorRossmeislová, Lenka
dc.contributor.authorAnděl, Michal
dc.contributor.authorKarpe, Fredrik
dc.contributor.authorSchlesinger, Sabrina
dc.date.accessioned2023-12-29T09:40:41Z
dc.date.available2023-12-29T09:40:41Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.14178/2153
dc.description.abstractBACKGROUND: COVID-19, an infectious disease caused by SARS-CoV-2, was shown to be associated with an increased risk of new-onset diabetes. Mechanisms contributing to the development of hyperglycemia are still unclear. We aimed to study whether hyperglycemia is related to insulin resistance and/or beta cell dysfunction. MATERIALS AND METHODS: Survivors of severe COVID-19 but without a known history of diabetes were examined at baseline (T0) and after 3 (T3) and 6 (T6) months: corticosteroids use, indirect calorimetry, and OGTT. Insulin response and sensitivity (IS) were expressed as insulinogenic (IGI), disposition (DI), and Matsuda insulin sensitivity index (ISI). Resting energy expenditure (REE) and respiratory quotient (RQ) was calculated from the gas exchange and nitrogen losses. RESULTS: 26 patients (out of 37) with complete outcome data were included in the analysis (age ~59.0 years; BMI ~ 30.4, 35% women). Patients were hypermetabolic at T0 (30.3 +- 4.0 kcal/kg lean mass/day, ~120% predicted) but REE declined over 6 months (ΔT6-T0 mean dif. T6-T0 (95% CI): -5.4 (-6.8, -4.1) kcal/kg FFM/day, p < 0.0001). 17 patients at T0 and 13 patients at T6 had hyperglycemia. None of the patients had positive islet autoantibodies. Insulin sensitivity in T0 was similarly low in hyperglycemic (H) and normoglycemic patients (N) (T0 ISI(H) = 3.12 +- 1.23, ISI(N) = 3.47 +- 1.78, p = 0.44), whereas insulin response was lower in the H group (DI(H) = 3.05 +- 1.79 vs DI(N) = 8.40 +- 5.42, p = 0.003). Over 6 months ISI (ΔT6-T0 mean dif. T6-T0 for ISI (95% CI): 1.84 (0.45, 3.24), p = 0.01)) increased in the H group only. CONCLUSIONS: Patients with severe COVID-19 had increased REE and insulin resistance during the acute phase due to the infection and corticosteroid use, but these effects do not persist during the follow-up period. Only patients with insufficient insulin response developed hyperglycemia, indicating that beta cell dysfunction, rather than insulin resistance, was responsible for its occurrence.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.1038/s41387-023-00241-7
dc.rightsCreative Commons Uveďte původ 4.0 Internationalcs
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.titleSevere COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort studyen
dcterms.accessRightsopenAccess
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/legalcode
dc.date.updated2023-12-29T09:40:41Z
dc.subject.keywordCOVID-19en
dc.subject.keywordhyperglycemiaen
dc.subject.keywordbeta cell dysfunctionen
dc.subject.keywordprospective cohort studyen
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/GA0/GA/GA22-22398S
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5104
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/SVV/SVV260531
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/COOP/COOP
dc.date.embargoStartDate2023-12-29
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.1038/s41387-023-00241-7
dc.identifier.utWos001031355100001
dc.identifier.eidScopus2-s2.0-85165034475
dc.identifier.obd633682
dc.identifier.pubmed37460458
dc.subject.rivPrimary30000::30200::30202
dcterms.isPartOf.nameNutrition & Diabetes
dcterms.isPartOf.issn2044-4052
dcterms.isPartOf.journalYear2023
dcterms.isPartOf.journalVolume13
dcterms.isPartOf.journalIssueJuly
uk.faculty.primaryId110
uk.faculty.primaryName3. lékařská fakultacs
uk.faculty.primaryNameThird Faculty of Medicineen
uk.department.primaryId110
uk.department.primaryName3. lékařská fakultacs
uk.department.primaryNameThird Faculty of Medicineen
uk.department.secondaryId100027057758
uk.department.secondaryId633
uk.department.secondaryId581
uk.department.secondaryNameÚstav hygieny 3. LF UKcs
uk.department.secondaryNameDepartment of Hygiene 3FM CUen
uk.department.secondaryNameInterní klinika 3. LF UK a FNKVcs
uk.department.secondaryNameDepartment of Internal Medicine 3FM CU and UHKVen
uk.department.secondaryNameÚstav patofyziologie 3. LF UKcs
uk.department.secondaryNameDepartment of Pathophysiology 3FM CUen
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::původní článekcs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::original articleen
dc.type.obdHierarchyCode73::152::206en
uk.displayTitleSevere COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort studyen


Soubory tohoto záznamu

Thumbnail

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam